<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02460276</url>
  </required_header>
  <id_info>
    <org_study_id>NLG-MCL6</org_study_id>
    <nct_id>NCT02460276</nct_id>
  </id_info>
  <brief_title>A Trial of Ibrutinib, Lenalidomide and Rituximab for Patients With Relapsed/Refractory Mantle Cell Lymphoma</brief_title>
  <acronym>PHILEMON</acronym>
  <official_title>A Phase II Trial of Ibrutinib, Lenalidomide and Rituximab for Patients With Relapsed/Refractory Mantle Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lund University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celgene</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Janssen, LP</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nordic Lymphoma Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Lund University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this trial, patients with mantle cell lymphoma will be included, treatment with&#xD;
      lenalidomide, rituximab and ibrutinib will be administered in an induction phase for up to 12&#xD;
      cycles, cycle length 28 days. Patients with complete remission, partial response or stable&#xD;
      disease will enter a maintenance phase with treatment with ibrutinib and rituximab until&#xD;
      progression of disease.&#xD;
&#xD;
      The primary objective is to evaluate overall response rate, based on PET and CT.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Actual">December 31, 2019</completion_date>
  <primary_completion_date type="Actual">December 31, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate.</measure>
    <time_frame>Change of tumor burden meassured from baseline during treatment of maximum 144 weeks.</time_frame>
    <description>Tumor evaluation will be performed with CT/PET for maximum 144 weeks. Discontinuation of evaluation if the patient develops progressive disease.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Relapsed/Refractory Mantle Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Lenalidomide, ibrutinib and rituximab.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide</intervention_name>
    <arm_group_label>Lenalidomide, ibrutinib and rituximab.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibrutinib</intervention_name>
    <arm_group_label>Lenalidomide, ibrutinib and rituximab.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <arm_group_label>Lenalidomide, ibrutinib and rituximab.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age over 18 years&#xD;
&#xD;
          -  Histologically confirmed (according to the WHO 2008, and upcoming 2015 classification)&#xD;
             mantle cell lymphoma stage II-IV&#xD;
&#xD;
          -  Received at least 1 prior rituximab-containing chemotherapy regimen&#xD;
&#xD;
          -  Documented relapse or disease progression following the last anti-mantle cell lymphoma&#xD;
             treatment&#xD;
&#xD;
          -  At least 1 measurable site of disease (over 1.5 cm long axis)&#xD;
&#xD;
          -  WHO performance status 0-3&#xD;
&#xD;
          -  Written informed concent&#xD;
&#xD;
          -  Female subjects of childbearing potential must:&#xD;
&#xD;
               1. Understand that the study medication is expected to have a teratogenic effect&#xD;
&#xD;
               2. Agree to use, and be able to comply with, highly effective contraception without&#xD;
                  interruption, 4 weeks Before start study drug, throughout study drug therapy&#xD;
                  (including dose interruptions) and for 12 months after the end of study drug&#xD;
                  therapy, even if she has amenorrhoea&#xD;
&#xD;
               3. Women of childbearing potential must have a negative serum (beta-human ionic&#xD;
                  gonadotropin or urine pregnancy test at screening. Women who are pregnant or&#xD;
                  breastfeeding are ineligible for this study&#xD;
&#xD;
          -  Male subjects must:&#xD;
&#xD;
               1. Agree to use condoms throughout study drug therapy, during any dose interruption&#xD;
                  and for 3 months after cessation of study therapy if their partner is of&#xD;
                  childbearing potential and has no contraception&#xD;
&#xD;
               2. Agree not to donate semen during study drug therapy and for 3 months after end of&#xD;
                  study drug therapy&#xD;
&#xD;
          -  All subjects must agree to abstain from donating blood while taking study drug therapy&#xD;
             and for one week following discontinuation of study drug therapy&#xD;
&#xD;
          -  All subjects must agree not to share study medication with another person and to&#xD;
             return all unused study drug to the investigator&#xD;
&#xD;
          -  Absolute neutrophil Count (ANC) ≥ 1000/mm3&#xD;
&#xD;
          -  Platelets ≥ 100,000/mm3 or ≥50,000/mm3 if bone marrow involvement independent of&#xD;
             transfusion support in either situation&#xD;
&#xD;
          -  Alanine aminotransferase (ALT) and aspartate aminotransferase ≤ 3 x upper limit of&#xD;
             normal (ULN).&#xD;
&#xD;
          -  Total bilirubin ≤ 1.5 x ULN unless bilirubin rise is due to Gilbert's syndrome or of&#xD;
             non-hepatic origin&#xD;
&#xD;
          -  Serum creatinine ≤ 2 x ULN or estimated Glomerular Filtration Rate (Cockcroft-Gault) ≥&#xD;
             40 mL/min/1.73 m2&#xD;
&#xD;
          -  Sign (or their legally-acceptable representatives must sign) an informed consent&#xD;
             document indicating that they understand the purpose of and procedures required for&#xD;
             the study, including biomarkers, and are willing to participate in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Chemotherapy or radiotherapy within 3 weeks, therapeutic antibodies within 4 weeks,&#xD;
             radioimmunotherapy within 10 weeks, or major surgery within 4 weeks of inclusion&#xD;
&#xD;
          -  Known central nervous system lymphoma&#xD;
&#xD;
          -  Other active malignancy&#xD;
&#xD;
          -  Psychiatric illness or condition which could interfere with the subjects' ability to&#xD;
             understand the requirements of the study&#xD;
&#xD;
          -  Requirement of corticosteroid therapy at a dose &gt; 10 mg prednisolone/day&#xD;
&#xD;
          -  Major surgery within 4 weeks of inclusion&#xD;
&#xD;
          -  History of stroke or intracranial hemorrhage within 6 months prior to inclusion&#xD;
&#xD;
          -  Requirement of anticoagulation treatment with warfarin or equivalent vitamin K&#xD;
             antagonists (eg, phenprocoumon)&#xD;
&#xD;
          -  Requirement of treatment with strong or moderate CYP3A inhibitors&#xD;
&#xD;
          -  Clinically significant cardiovascular disease such as uncontrolled or symptomatic&#xD;
             arrythmias, congestive heart failure, or myocardial infarction within 6 months of&#xD;
             screening, or any Class 3 (moderate) or Class 4 (severe) cardiac disease as defined by&#xD;
             the New York Heart Association Functional Classification&#xD;
&#xD;
          -  Vaccination with live, attenuated vaccines within 4 weeks of inclusion&#xD;
&#xD;
          -  Known history of human immunodeficiency virus (HIV) or Active hepatitis C Virus or&#xD;
             Active Hepatitis B Virus infection or any uncontrolled Active systemic infection&#xD;
             requiring intravenous antibiotics&#xD;
&#xD;
          -  Any Life-threatening illness, Medical condition, or organ system dysfunction which, in&#xD;
             the investigator's opinion, could compromise the subject's safety, interfere with the&#xD;
             absorption or metabolism of ibrutinib capsules or lenalidomide tablets, or put the&#xD;
             study outcomes at undue risk&#xD;
&#xD;
          -  Known hypersensitivity or allergy to rituximab, lenalidomide or ibrutinib&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helsinki University Hospital</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norwegian Radium Hospital</name>
      <address>
        <city>Oslo</city>
        <zip>0424</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lund University Hospital</name>
      <address>
        <city>Lund</city>
        <zip>221 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uppsala Akademiska Hospital</name>
      <address>
        <city>Uppsala</city>
        <zip>751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Finland</country>
    <country>Norway</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>May 26, 2015</study_first_submitted>
  <study_first_submitted_qc>May 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 2, 2015</study_first_posted>
  <last_update_submitted>April 22, 2020</last_update_submitted>
  <last_update_submitted_qc>April 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mantle cell lymphoma</keyword>
  <keyword>Relapsed mantle cell lymphoma</keyword>
  <keyword>Lenalidomide</keyword>
  <keyword>Rituximab</keyword>
  <keyword>Ibrutinib</keyword>
  <keyword>Response duration</keyword>
  <keyword>Complete remission rate</keyword>
  <keyword>Quality of life</keyword>
  <keyword>Overall survival</keyword>
  <keyword>Safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

